Literature DB >> 3380956

Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT.

G Sze1, J Shin, G Krol, C Johnson, D Liu, M D Deck.   

Abstract

Prospective and retrospective studies of 75 patients were performed to assess the sensitivities of magnetic resonance (MR) imaging and computed tomography (CT) in the evaluation of suspected intraparenchymal brain metastases. The findings on MR images were equivalent to those on CT scans in 49 of the 75 patients; the remaining findings were discordant in 26 patients, and neither MR imaging nor CT was consistently superior. MR imaging demonstrated more metastases in nine of these 26 patients. However, contrast material-enhanced CT scans were superior in lesion depiction in eight of the 26 patients. Large enhanced lesions that were nearly isointense on MR images were seen well on CT scans. In several cases in which results were discordant, gadolinium-diethylenetriaminepentaacetic acid (DTPA)-enhanced MR images were obtained, and this agent behaved similarly to iodinated contrast agents. If indicated clinically, such as before surgery for a single metastasis, the authors perform both MR imaging and contrast-enhanced CT. Gd-DTPA-enhanced MR imaging may prove to be the method of choice for depiction of intraparenchymal metastases.

Entities:  

Mesh:

Year:  1988        PMID: 3380956     DOI: 10.1148/radiology.168.1.3380956

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  New applications of MR contrast agents in neuroradiology.

Authors:  G Sze
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Value of contrast enhanced CT scanning in the non-trauma emergency room patient.

Authors:  L P Wood; M Parisi; I J Finch
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

3.  Diagnostic accuracy of MRI compared to CCT in patients with brain metastases.

Authors:  P D Schellinger; H M Meinck; A Thron
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  Comparative study of vascular enhancement on post-contrast CT using three dosages of iodinated contrast media for the aim of detecting brain metastasis in patients with lung cancer.

Authors:  Katsumi Hayakawa; Toshiki Shiozaki; Akira Yamamoto; Soichi Kubo; Tsutomu Osako
Journal:  Radiat Med       Date:  2006-02

5.  Imaging of brain metastases. Comparison of computerized tomography (CT) and magnetic resonance imaging (MRI).

Authors:  M J Taphoorn; J J Heimans; M C Kaiser; R G de Slegte; F C Crezee; J Valk
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

Review 6.  The clinical application of radiopharmaceuticals.

Authors:  N E Leeds
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

7.  Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.

Authors:  Klaus Strobel; Jeannine Skalsky; Victor Kalff; Katrin Baumann; Burkhardt Seifert; Helen Joller-Jemelka; Reinhard Dummer; Hans C Steinert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-28       Impact factor: 9.236

8.  Identification of intracranial liqor metastases of experimental stereotactically implanted brain tumors by the tumor-selective MRI contrast agent MnTPPS.

Authors:  R I Ernestus; L J Wilmes; M Hoehn-Berlage
Journal:  Clin Exp Metastasis       Date:  1992-09       Impact factor: 5.150

Review 9.  Current approaches to the management of brain metastases.

Authors:  John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang
Journal:  Nat Rev Clin Oncol       Date:  2020-02-20       Impact factor: 66.675

10.  Imaging of brain metastases.

Authors:  Kathleen R Fink; James R Fink
Journal:  Surg Neurol Int       Date:  2013-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.